Chimeric Antigen Receptor News and Research

RSS

New gene modification enhances CAR-T cell effectiveness against cancer

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for an extended period, potentially reducing the chance of cancer recurring.

7 Feb 2025

Study reveals mechanism behind CAR molecule transfer in cancer therapy

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now discovered that CAR molecules can be transferred from the CAR-T cells to other T cells in the tumour microenvironment.

3 Feb 2025

T cells grown with new technique offer better cancer defense

Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared to those grown in traditional growth media.

28 Jan 2025

Updated guidelines for preventing and managing hepatitis B virus reactivation

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

27 Jan 2025

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs.

23 Jan 2025

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

New drug cocktail enhances CAR-T cells for cancer treatment

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen receptor-T cells) to fight cancer.

13 Jan 2025

Research explores molecular dynamics of CAR T cells in cancer treatment

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer.

10 Jan 2025

New therapeutic target could boost CAR T-cell therapy success in solid tumors

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, "TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids".

10 Jan 2025

CAR-T cells carry memory of past antigen encounters

Researchers at the University of Colorado Anschutz Medical Campus have discovered that some CAR-T cells engineered to fight cancer and other conditions carry the memory of past encounters with bacteria, viruses and other antigens within them, a finding that may allow scientists to manufacture the cells in more precise and targeted ways.

2 Jan 2025

New approach in fighting leukemia with double-modified natural killer cells

Various forms of blood cancer exist – all of which are grouped together under the term leukemia. One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation of early blood cell precursors, i.e. stem cells and the precursor cells that develop from them.

18 Dec 2024

Nutrient metabolism regulates T cell exhaustion and therapy potential

Findings reveal that metabolic enzymes ACSS2 and ACLY regulate T cell exhaustion, linking nutrient metabolism to epigenetic changes in immunity.

17 Dec 2024

New $1.4M grant supports innovative kidney cancer treatment strategy

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

10 Dec 2024

Ultrasound-controlled CRISPR offers precision in treating genetic disorders

Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our most challenging genetic disorders and diseases.

4 Dec 2024

IL-15 improves the effectiveness of GPC3 CAR T cells in targeting solid tumors

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in patients with solid cancers.

2 Dec 2024

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

2 Dec 2024

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

27 Nov 2024

Revolutionary strategy offers hope for type 1 diabetes treatment

Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no longer have to rely on donors. Organ shortages and cell type mismatches will become past problems, replaced by safe, on-demand options for anyone who needs a transplant.

25 Nov 2024

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute (HMRI), Barcelona, have developed novel chimeric antigen receptor (CAR) T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

19 Nov 2024

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects, paving the way for advanced synthetic biology applications.

17 Nov 2024